We intend to capitalize on our management team’s background to identify and acquire a business in the life sciences industry. In particular, we will target companies in the biotechnology sector where our management team has extensive experience with a focus on identifying target businesses in developed countries including, but not limited to, the United States and countries in Europe. We may pursue a transaction in which our shareholders immediately prior to the completion of our initial business combination would collectively own a minority interest in the post-business combination company.

Our sponsor, Consonance Life Sciences, combines life sciences and biotechnology investing expertise and market knowledge with industry-based business development, transactional and operational experience. Consonance Life Sciences was formed by the founders of Consonance Capital Management, a leading healthcare-dedicated hedge fund manager, and then partnered with a dedicated team of biotechnology industry professionals with extensive experience identifying attractive and unique acquisition opportunities. 

(Note: The size of this SPAC IPO was cut by 20 percent to 80 million units, down from 100 million units initially, at the same price of $10 per unit, according to an SEC filing dated Nov. 12. The deal was among those set for pricing on Oct. 22, but it was not priced that night. On Nov. 4, the SPAC filed with the SEC to change its listing to the NYSE American from the NYSE.)